Veru Inc. is a Florida-based oncology biopharmaceutical company that specializes in developing cancer management drugs, including treatments for breast and prostate cancer. Their product FC2 female condom provides dual protection to minimize the risk of sexually transmitted infections and unintended pregnancies. The company's clinical trial pipeline includes several drug candidates, such as Enobosarm and Sabizabulin, that target various forms of cancer and inflammation.